Introduction {#s1}
============

Molecular profiling to identify potential therapeutic targets has been widely applied in common tumors such as lung cancer ([@B1], [@B2]), breast cancer ([@B3], [@B4]), melanoma ([@B5]), and colorectal cancer ([@B6], [@B7]). The use of targeted therapy in selected patients can significantly improve outcomes. Increasingly, clinical trials feature targeted therapeutic agents or require a specific biomarker for entry ([@B8], [@B9]). However, limited information is available regarding the utility of targeted therapy for rare tumors ([@B10], [@B11]). What\'s more, while rare individually, rare tumors cumulatively account for over 20% of adult malignant neoplasms in the United States ([@B12], [@B13]).

There is no universally applied definition for rare tumors ([Table 1](#T1){ref-type="table"}). The European Society for Medical Oncology (ESMO) defines a rare tumor as a tumor with an annual incidence of 6/10,000 ([@B14]) in Europe. The National Cancer Institute (NCI) (<https://www.cancer.gov/publications/dictionaries/cancer-terms/def/791790>) and Food and Drug Administration (FDA) (<http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2789814/>) defines it as a tumor with an annual incidence of \<15/10,000 in the US. According to the NCI definition, lung cancer, colon cancer, breast cancer, prostate cancer, endometrial carcinoma, rectal cancer, ovarian cancer, kidney cancer, melanoma, non-Hodgkin lymphoma, and gastric cancer belong to common cancers.

###### 

Worldwide rare tumor prevalence.

  **Source**   **Type**       **Definition**          **Link for information**
  ------------ -------------- ----------------------- -----------------------------------------------------------------------------
  FDA          Rare disease   \<200,000 in US         <https://www.fda.gov/industry/developing-products-rare-diseases-conditions>
               Rare tumor     \<15/100,000 per year   <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2789814/>
  NCI          Rare cancer    \<15/100,000 per year   <https://www.cancer.gov/publications/dictionaries/cancer-terms/def/791790>
  EMA          Rare disease   \<1/2000                <http://www.eurordis.org/about-rare-diseases>
               Rare tumor     \<6/100,000 per year    <http://www.rarecancerseurope.org/About-Rare-Cancers>

There is some discordance between these definitions and data specific to China. While esophageal cancer and hepatocellular carcinoma are rare tumors according to NCI definition, these are common in China based on annual incidence. On the other hand, skin tumors, especially basal cell carcinoma, are common tumors in the United States, with an incidence of 255.6/100,000 ([@B15]), but are relatively rare in China ([@B14]) (2.4/100,000 for all skin tumors). This suggests that the definitions from US and Europe were possibly not appropriate in China based on the different incidences and prevalence of tumors.

This study analyzed data from the National Cancer Registry office of the National Cancer Center ([@B16]) and integrated it with presently available treatment options to generate a definition of rare tumors specific to China. Subsequently, available data for targetable genomic alterations (TGAs) of two cohorts of rare tumors from the cBioPortal and Geneplus databases were collected and analyzed. Our work provides valuable knowledge to guide personalized, targeted therapy for rare tumors.

Methods {#s2}
=======

Definition of Rare Tumors in China
----------------------------------

We consulted National Cancer Registry of the National Cancer Center, China ([@B16]) and generated an estimation of incidence of tumors in mainland China. Tumor types were classified according to the International Classification of Diseases (ICD), and we comprehensively synthesized the epidemiology data and availability of standard treatment in China as well as opinions of experts from National Cancer Center. We then defined rare tumors in China according to the following standardizations ([Table 2](#T2){ref-type="table"}):

1.  First, we eliminated the tumors from systems or organs which have consensus or guidelines for treatment in China; an incidence of "2.5/100,000 per year" was selected as a cut-off value for "rare tumor" for tumors with unique ICD codes listed with systems or organs;

2.  Secondly, we searched OncoTrees (<http://oncotree.mskcc.org/>) to further investigate the subtypes of those common tumors that ([@B1]) have a distinct ICD code and ([@B2]) exhibit an incidence \>2.5/100,000 per year in China. We included subtypes of those tumors after further confirming that the incidence of which was ≤2.5/100,000 per year in China by searching Pubmed database (<https://www.ncbi.nlm.nih.gov/pubmed/>) and the China National Knowledge Infrastructure (CNKI) database;

3.  Finally, we also included cancers of unknown primary (CUP) tumors, not only because the incidence of those tumors was ≤2.5/100,000 per year in China, but also because there were no consensus or guidelines for treatment of CUP in China.

###### 

Rare tumors with limited therapeutic strategy in China.

  **System**      **ICD**    **Site**                           **Tumors subtypes**
  --------------- ---------- ---------------------------------- -----------------------------------------------------------------------------------------------------
  Digestive       C24        Biliary tract                      Perihilar cholangiocarcinoma
  Digestive       C24        Biliary tract                      Extrahepatic cholangiocarcinoma
  Digestive       C24        Biliary tract                      Intrahepatic cholangiocarcinoma
  Digestive       C24        Biliary tract                      Pancreatobiliary ampullary carcinoma
  Digestive       C23        Gallbladder                        Gallbladder cancer
  Digestive       C17        Small bowel                        Small bowel well-differentiated neuroendocrine tumor
  Digestive       C17        Small bowel                        Duodenal adenocarcinoma
  Digestive       C17        Small bowel                        Small intestinal carcinoma
  Digestive       C22        Liver                              Hepatoblastoma
  Digestive       C22        Liver                              Liver Angiosarcoma
  Digestive       C25        Pancreas                           Pancreatoblastoma
  Digestive       C18        Colon                              Medullary Carcinoma Of The Colon
  Endocrine       C74        Adrenal                            Adrenocortical carcinoma
  Endocrine       C75        Pituitary                          Pituitary carcinoma
  Endocrine       C73        Thyroid                            Medullary thyroid cancer
  Neural system   C72, C70   Brain                              Anaplastic astrocytoma
  Neural system   C72, C70   Brain                              Anaplastic oligodendroglioma
  Neural system   C72, C70   Brain                              Anaplastic oligoastrocytoma
  Neural system   C72, C70   Brain                              Glioblastoma
  Neural system   C72, C70   Brain                              Astrocytoma
  Neural system   C72, C70   Brain                              Diffuse intrinsic pontine glioma
  Neural system   C72, C70   Brain                              Oligodendroglioma
  Neural system   C72, C70   Brain                              Oligoastrocytoma
  Neural system   C72, C70   Brain                              High-grade glioma(NOS)
  Neural system   C72, C70   Brain                              Primitive neuroectodermal tumor
  Neural system   C72, C70   Brain                              Olfactory neuroblastoma
  Neural system   C72, C70   Brain                              Medulloepithelioma
  Neural system   C72, C70   Brain                              Medulloblastoma
  Neural system   C72, C70   Brain                              Medullomyoblastoma
  Neural system   C72, C70   Brain                              Ganglioneuroblastoma
  Neural system   C72, C70   Brain                              Melanotic medulloblastoma
  Neural system   C72, C70   Brain                              Medulloblastoma with extensive nodularity
  Neural system   C72, C70   Brain                              Embryonal tumor with abundant neuropil and true rosettes
  Neural system   C72, C70   Brain                              Atypical teratoid/rhabdoid tumor
  Neural system   C72, C70   Brain                              Large cell/anaplastic medulloblastoma
  Neural system   C72, C70   Brain                              Desmoplastic/nodular medulloblastoma
  Neural system   C72, C70   Brain                              Neuroblastoma
  Neural system   C72, C70   Brain                              Hemangioblastoma
  Neural system   C72, C70   Brain                              Mesenchymal chondrosarcoma of the CNS
  Neural system   C72, C70   Brain                              Papillary meningioma
  Neural system   C72, C70   Brain                              Atypical meningioma
  Neural system   C72, C70   Brain                              Anaplastic meningioma
  Neural system   C72, C70   Brain                              Clear cell meningioma
  Neural system   C72, C70   Brain                              Meningioma
  Neural system   C72, C70   Brain                              Chordoid meningioma
  Neural system   C72, C70   Brain                              Rhabdoid meningioma
  Neural system   C72, C70   Brain                              Malignant teratoma
  Neural system   C72, C70   Brain                              Embryonal Carcinoma
  Neural system   C72, C70   Brain                              Choriocarcinoma
  Neural system   C72, C70   Brain                              Astroblastoma
  Neural system   C72, C70   Brain                              Ependymoma
  Neural system   C72, C70   Brain                              Anaplastic ependymoma
  Neural system   C47        Peripheral nerve                   Malignant peripheral nerve sheath tumor
  Reproductive    C60        Penile                             Penile squamous cell carcinoma
  Reproductive    C52, C51   Vulva/vagina                       Squamous cell carcinoma of the vulva/vagina
  Reproductive    C52, C51   Vulva/vagina                       Vaginal adenocarcinoma
  Reproductive    C52, C51   Vulva/vagina                       Mucinous adenocarcinoma of the vulva/vagina
  Reproductive    C52, C51   Vulva/vagina                       Poorly differentiated vaginal carcinoma
  Reproductive    C52, C51   Vulva/vagina                       Germ cell tumor of the vulva
  Reproductive    C61        Prostate                           Prostate small cell carcinoma
  Reproductive    C54        Uterus                             Uterine adenosarcoma
  Reproductive    C54        Uterus                             Endometrial stromal sarcoma
  Reproductive    C56        Ovary                              Dysgerminoma
  Reproductive    C56        Ovary                              Ovarian carcinosarcoma/malignant mixed mesodermal tumor
  Reproductive    C56        Ovary                              Brenner tumor, malignant
  Reproductive    C56        Ovary                              Clear cell ovarian cancer
  Reproductive    C56        Ovary                              Endometrioid ovarian cancer
  Reproductive    C56        Ovary/vulva/vagina/brain/testis,   Embryonal carcinoma
  Soft tissue     C49        Soft tissue                        Desmoplastic small-round-cell tumor
  Soft tissue     C49        Soft tissue                        Low-grade fibromyxoid sarcoma
  Soft tissue     C49        Soft tissue                        Rhabdomyosarcoma
  Soft tissue     C49        Soft tissue                        Synovial sarcoma
  Soft tissue     C49        Soft tissue                        Myofibroma
  Soft tissue     C49        Soft tissue                        Myopericytoma
  Soft tissue     C49        Soft tissue                        Myxofibrosarcoma
  Soft tissue     C49        Soft tissue                        Leiomyosarcoma
  Soft tissue     C49        Soft tissue                        Aggressive angiomyxoma
  Soft tissue     C49        Soft tissue                        Soft tissue myoepithelial carcinoma
  Soft tissue     C49        Soft tissue                        Alveolar soft part sarcoma
  Soft tissue     C49        Soft tissue                        Epithelioid sarcoma
  Soft tissue     C49        Soft tissue                        Epithelioid hemangioendothelioma
  Soft tissue     C49        Soft tissue                        Dendritic cell sarcoma
  Soft tissue     C49        Soft tissue                        Clear cell sarcoma
  Soft tissue     C49        Soft tissue                        Undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma/high-grade spindle cell sarcoma
  Soft tissue     C49        Soft tissue                        Gastrointestinal stromal tumor
  Soft tissue     C49        Soft tissue                        Sarcoma (NOS)
  Soft tissue     C49        Soft tissue                        Fibrosarcoma
  Soft tissue     C49        Soft tissue                        Hemangioma
  Soft tissue     C49        Soft tissue                        Intimal sarcoma
  Soft tissue     C49        Soft tissue                        Glomangiosarcoma
  Soft tissue     C49        Soft tissue                        Angiosarcoma
  Soft tissue     C49        Soft tissue                        Inflammatory myofibroblastic tumor
  Soft tissue     C49        Soft tissue                        Desmoid/aggressive fibromatosis
  Soft tissue     C49        Soft tissue                        Liposarcoma
  Bone            C40, C41   Bone                               Chondrosarcoma
  Bone            C40, C41   Bone                               Chordoma
  Bone            C40, C41   Bone                               Osteosarcoma
  Bone            C40, C41   Bone                               Ewing sarcoma
  Skin            C44        Skin                               Basal cell carcinoma
  Skin            C44        Skin                               Dermatofibrosarcoma protuberans
  Skin            C44        Skin                               Merkel cell carcinoma
  Skin            C44        Skin                               Cutaneous Squamous Cell Carcinoma
  Skin            C44        Skin                               Aggressive digital papillary adenocarcinoma
  Skin            C44        Skin                               Sebaceous carcinoma
  Skin            C44        Skin                               Skin adnexal carcinoma
  Skin            C44        Skin                               Sweat gland adenocarcinoma
  Skin            C44        Skin                               Sweat gland carcinoma/apocrine eccrine carcinoma
  Lung            C39        Lung                               Mucoepidermoid carcinoma of the lung
  Lung            C39        Lung                               Spindle cell carcinoma of the lung
  Lung            C39        Lung                               Lymphoepithelioma-like carcinoma of the lung
  Lung            C39        Lung                               Giant cell carcinoma of the lung
  Lung            C39        Lung                               Basaloid large cell carcinoma of the lung
  Lung            C39        Lung                               Clear cell carcinoma of the lung
  Lung            C39        Lung                               Adenoid cystic carcinoma of the lung
  Lung            C39        Lung                               Mucoepidermoid carcinoma of the lung
  Lung            C39        Lung                               Sarcomatoid carcinoma of the lung
  Breast          C50        Breast                             Breast invasive carcinosarcoma
  Breast          C50        Breast                             Adenoid cystic breast cancer
  Breast          C50        Breast                             Breast carcinoma with signet ring
  Breast          C50        Breast                             Breast invasive mixed mucinous carcinoma
  Urinary         C67        Bladder                            Plasmacytoid/signet ring cell bladder carcinoma
  Urinary         C67        Bladder                            Sarcomatoid carcinoma of the urinary bladder
  Urinary         C67        Bladder                            Small cell bladder cancer
  Urinary         C64        Kidney                             Renal non-clear cell carcinoma
  Others          C45, C48   Pleura, Peritonea                  Pleural mesothelioma
  Others          C45, C48   Pleura, Peritonea                  Pleuropulmonary blastoma
  Others          C45, C48   Pleura, peritonea                  Peritoneal mesothelioma
  Others          C38        Heart                              Primary heart malignant tumor
  Others          C37        Thymus                             Thymic carcinoma
  Others          C06        Head and neck                      Acinic cell carcinoma
  Others          C06        Head and neck                      Adenoid cystic carcinoma
  Others          C06        Head and neck                      Mammary analogue secretory carcinoma of salivary gland origin
  Others          C06        Head and neck                      Mucoepidermoid carcinoma
  Others          C06        Head and neck                      Myoepithelial carcinoma
  Others          C06        Head and neck                      Salivary adenocarcinoma
  Others          C06        Head and neck                      Salivary duct carcinoma
  Others          C06        Head and neck                      Epithelial-myoepithelial carcinoma
  Others          C06        Head and neck                      Clear cell odontogenic carcinoma
  Others          C06        Head and neck                      Sinonasal adenocarcinoma
  Others          C06        Head and neck                      Sinonasal undifferentiated carcinoma
  Others          C80, C76   Unknown                            Cancer of unknown primary

Definition of Targetable Mutations According to the OncoKB Framework
--------------------------------------------------------------------

The actionabilities of genetic alterations were mainly based on the OncoKB knowledge database (<https://oncokb.org>). Utilizing the OncoKB framework, mutations could be classified into 4 main levels of evidence for biomarker-guided therapy and those with unknown significance. OncoKB is a precision oncology knowledge base and contains information about the effects and treatment implications of specific cancer gene alterations. It is developed and maintained by the Knowledge Systems group in the Marie Josée and Henry R. Kravis Center for Molecular Oncology at Memorial Sloan Kettering Cancer Center (MSK) ([@B17]). Curated by a network of clinical fellows, research fellows, and faculty members at MSK, OncoKB contains detailed information about specific alterations in 668 cancer genes. The information is compiled from various sources, such as guidelines from the FDA, NCCN, or ASCO, [ClinicalTrials.gov](https://www.ClinicalTrials.gov) and the scientific literature. Level 1 is an FDA-recognized biomarker predictive of response to an FDA-approved drug in this indication. Level 2 is standard care biomarker predictive of response to an FDA-approved drug in this indication (2A) or in another indication, but not standard care in this indication (2B). Level 3 is compelling clinical evidence supports the biomarker as being predictive of response to a drug in this indication (3A) or in another indication (3B). Level 4 is compelling biological evidence supports the biomarker as being predictive of response to a drug ([Supplementary Table 1](#SM1){ref-type="supplementary-material"}).

cBioPortal
----------

The cBioPortal for Cancer Genomics was originally developed at Memorial Sloan Kettering Cancer Center. The public cBioPortal site is hosted by the Center for Molecular Oncology at MSK. The cBioPortal currently hosts more than 40 datasets, including TCGA and other large-scale genomic studies, and makes them available for bulk download. Data from OCG\'s TARGET Initiative will be added to the database in the next year. The data types from the 13,000+ tumor samples include mutations, copy number alterations, mRNA expression changes, and DNA methylation values, as well as clinical parameters, such as disease-free survival.

(<https://www.cbioportal.org/datasets>).

Estimation of Targetable Mutations
----------------------------------

To estimate the prevalence of targetable mutations in rare tumors, we queried the cBioPortal database using the genes listed in [Supplementary Table 1](#SM1){ref-type="supplementary-material"} in a manually curated set of 175 non-redundant studies, including TCGA and non-TCGA studies, with no overlapping samples. Mutations of those genes were downloaded and filtered with the annotated oncoKB levels of evidence. Only mutations of level 1-4 were kept for further analysis. To calculate the prevalence, the cumulative number of targetable mutations in each cancer was divided by total numbers of samples for that cancer. The same criteria and workflow were used for the Chinese patient cohort.

Patient Recruitment
-------------------

We retrospectively analyzed genomic profiling data of 1,312 patients with rare tumors from Geneplus database. This database contained patients enrolled from multiple hospitals of China from September 2015 to October 2019 ([@B18], [@B19]). All patients received next-generation sequencing (NGS) testing in Geneplus-Beijing Institute after obtaining written informed consent. Meanwhile, all the patients were stratified into different clinicopathological subgroups according to OncoTree system (<http://oncotree.mskcc.org/>).

All tissues samples included in this study underwent an onsite pathology review to confirm histologic classification and tumor tissue adequacy, which required a minimum of 20% of tumor cells. Genomic profiling was performed in a College of American Pathologists--accredited laboratory (Geneplus-Beijing) using the Illumina Nextseq CN 500 or Gene+Seq 2000 instrument ([@B20], [@B21]). Briefly, serial sections from formalin-fixed paraffin-embedded (FFPE) tumor tissues were used for genomic tumor DNA extraction using the QIAamp DNA mini kit (Qiagen, Valencia, CA). ctDNA was isolated from 4 to 5 mL of plasma using the QIAamp Circulating Nucleic Acid Kit (Qiagen, Valencia, CA). DNA from leukocytes was extracted using the DNeasy Blood Kit (Qiagen, Valencia, CA). Sequencing libraries were prepared from ctDNA using KAPA DNA Library Preparation Kits (Kapa Biosystems, Wilmington, MA, USA), and genomic DNA sequencing libraries were prepared with Illumina TruSeq DNA Library Preparation Kits (Illumina, San Diego, CA). Libraries were hybridized to custom-designed biotinylated oligonucleotide probes (Roche NimbleGen, Madison, WI, USA) targeting 59-1021 genes (\~1.4 Mbp genomic regions of 1021 cancer-related genes or \~230 Kbp genomic regions of 59 genes) ([Supplementary Tables 2](#SM2){ref-type="supplementary-material"}, [3](#SM3){ref-type="supplementary-material"}). Prepared libraries were sequenced on using the Illumina Nextseq CN 500 (Illumina, San Diego, CA) or Gene+Seq 2000 (Geneplus-Beijing, China).

Sequencing data were analyzed using default parameters. Adaptor sequences and low-quality reads were removed. The clean reads were aligned to the reference human genome (hg19) using Burrows-Wheeler Aligner (BWA; version 0.7.12-r1039). Realignment and recalibration were performed using GATK (version 3.4-46-gbc02625). Single nucleotide variants (SNV) were called using MuTect (version 1.1.4) and NChot, a software developed in-house to review hotspot variants ([@B22]). Small insertions and deletions (InDels) were determined by GATK. Somatic copy number alterations were identified with CONTRA (v2.0.8). The final candidate variants were all manually verified using Integrative Genomics Viewer.

Targeted capture sequencing required a minimal mean effective depth of coverage of 300× in tissues and 1,000× in plasma samples. For the 1,312 patients included in our study, the mean effective depth of coverage is 1,295× in tissues and 2,014× in plasma samples and 299× in germline DNA samples ([Supplementary Table 4](#SM4){ref-type="supplementary-material"}).

TGAs simultaneously detected by this assay included base substitutions, short insertions and deletions, focal gene amplifications and homozygous deletions (copy number alterations) and select gene fusions and rearrangements. Variants were filtered to exclude synonymous variants, known germline variants in dbSNP, and variants that occur at a population frequency of \>1% in the Exome Sequencing Project. Germline variants were interpreted following ACMG guidelines, and the variants were classified as pathogenic, likely pathogenic, unknown significance, likely benign, and benign.

Statistics
----------

The Chi-square test or Fisher\'s exact test was performed to compare frequency targetable mutations between groups. All statistical analysis was performed with SPSS (v.23.0; STATA, College Station, TX, USA) or GraphPad Prism (v. 6.0; GraphPad Software, La Jolla, CA, USA) software. Statistical significance was defined as a two-sided *P*-value of \< 0.05.

Results {#s3}
=======

Mutation Profiling of Rare Tumors in cBioPortal Database
--------------------------------------------------------

Rare tumors according to our China-specific definition included 141 tumor types. We analyzed a total of 45,666 samples from the cBioPortal database and identified 4,901 samples of rare tumors that matched our definition, representing 63 of the 141 possible tumor types. Neuroblastoma, adenoid cystic carcinoma, Ewing sarcoma, astrocytoma, and oligodendroglioma were the top 5 rare tumors, with 1321, 323, 263, 250, and 229 samples, respectively. One thousand (20.4%, 1000/4901) targetable mutations were identified in the 4901 samples, with *PIK3CA, PTEN, KIT, CDKN2A, ATM, FGFR, BRAF, NF1, ALK*, and *BRCA2* as the top 10 genes with targetable mutations identified in 266, 149, 119, 112, 75, 66, 33, 33, 27, and 27 samples, respectively ([Table 3](#T3){ref-type="table"} and [Supplementary Table 5](#SM5){ref-type="supplementary-material"}).

###### 

Prevalence of targetable mutations in rare tumor samples from cBioPortal database.

  **System**      **ICD**    **Site**                           **Tumors, including but not restricted to**                                                           **All cases**   **Cases with targetable mutations**   **Prevalence of targetable mutations \# (%)**
  --------------- ---------- ---------------------------------- ----------------------------------------------------------------------------------------------------- --------------- ------------------------------------- -----------------------------------------------
  Digestive       C24        Biliary tract                      Perihilar cholangiocarcinoma                                                                          5               1                                     20.0
  Digestive       C24        Biliary tract                      Extrahepatic cholangiocarcinoma                                                                       27              7                                     25.9
  Digestive       C24        Biliary tract                      Intrahepatic cholangiocarcinoma                                                                       186             75                                    40.3
  Digestive       C24        Biliary tract                      Pancreatobiliary ampullary carcinoma                                                                  9               5                                     55.6
  Digestive       C23        Gallbladder                        Gallbladder cancer                                                                                    81              20                                    24.7
  Digestive       C17        Small bowel                        Duodenal adenocarcinoma                                                                               3               6                                     200.0
  Digestive       C18        Colon                              Medullary carcinoma of the colon                                                                      1               5                                     500.0
  Endocrine       C74        Adrenal                            adrenocortical carcinoma                                                                              118             8                                     6.8
  Endocrine       C73        Thyroid                            Medullary thyroid Cancer                                                                              17              12                                    70.6
  Neural system   C72, C70   Brain                              Anaplastic astrocytoma                                                                                110             36                                    32.7
  Neural system   C72, C70   Brain                              Anaplastic oligodendroglioma                                                                          52              20                                    38.5
  Neural system   C72, C70   Brain                              Glioblastoma                                                                                          15              17                                    113.3
  Neural system   C72, C70   Brain                              Astrocytoma                                                                                           250             46                                    18.4
  Neural system   C72, C70   Brain                              Diffuse intrinsic pontine glioma                                                                      3               1                                     33.3
  Neural system   C72, C70   Brain                              Oligodendroglioma                                                                                     229             41                                    17.9
  Neural system   C72, C70   Brain                              Oligoastrocytoma                                                                                      147             18                                    12.2
  Neural system   C72, C70   Brain                              Primitive neuroectodermal tumor                                                                       2               1                                     50.0
  Neural system   C72, C70   Brain                              Medulloblastoma                                                                                       166             8                                     4.8
  Neural system   C72, C70   Brain                              Neuroblastoma                                                                                         1,321           27                                    2.0
  Neural system   C72, C70   Brain                              Embryonal carcinoma                                                                                   36              1                                     2.8
  Neural system   C72, C70   Brain                              Choriocarcinoma                                                                                       11              1                                     9.1
  Neural system   C72, C70   Brain                              Ependymoma                                                                                            11              1                                     9.1
  Neural system   C72, C70   Brain                              Anaplastic ependymoma                                                                                 7               2                                     28.6
  Neural system   C47        Peripheral nerve                   Malignant peripheral nerve sheath tumor                                                               35              5                                     14.3
  Reproductive    C60        Penile                             Penile squamous cell carcinoma                                                                        6               5                                     83.3
  Reproductive    C52, C51   Vulva/vagina                       Squamous cell carcinoma of the vulva/vagina                                                           19              7                                     36.8
  Reproductive    C61        Prostate                           Prostate small cell carcinoma                                                                         7               6                                     85.7
  Reproductive    C56        Ovary                              Ovarian carcinosarcoma/malignant mixed mesodermal tumor                                               12              3                                     25.0
  Reproductive    C56        Ovary                              Endometrioid ovarian cancer                                                                           7               8                                     114.3
  Reproductive    C56        Ovary/vulva/vagina/brain/testis,   Embryonal carcinoma                                                                                   36              1                                     2.8
  Soft tissue     C49        Soft tissue                        Rhabdomyosarcoma                                                                                      54              6                                     11.1
  Soft tissue     C49        Soft tissue                        Synovial sarcoma                                                                                      44              3                                     6.8
  Soft tissue     C49        Soft tissue                        Myxofibrosarcoma                                                                                      32              4                                     12.5
  Soft tissue     C49        Soft tissue                        Leiomyosarcoma                                                                                        142             19                                    13.4
  Soft tissue     C49        Soft tissue                        Soft tissue myoepithelial carcinoma                                                                   6               2                                     33.3
  Soft tissue     C49        Soft tissue                        Undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma/high-grade spindle cell sarcoma   109             21                                    19.3
  Soft tissue     C49        Soft tissue                        Gastrointestinal stromal tumor                                                                        137             119                                   86.9
  Soft tissue     C49        Soft tissue                        Fibrosarcoma                                                                                          5               0                                     0.0
  Soft tissue     C49        Soft tissue                        Angiosarcoma                                                                                          84              24                                    28.6
  Soft tissue     C49        Soft tissue                        Inflammatory myofibroblastic tumor                                                                    7               2                                     28.6
  Bone            C40, C41   Bone                               Chondrosarcoma                                                                                        19              1                                     5.3
  Bone            C40, C41   Bone                               Chordoma                                                                                              14              2                                     14.3
  Bone            C40, C41   Bone                               Osteosarcoma                                                                                          43              5                                     11.6
  Bone            C40, C41   Bone                               Ewing sarcoma                                                                                         263             12                                    4.6
  Skin            C44        Skin                               Basal cell carcinoma                                                                                  12              5                                     41.7
  Skin            C44        Skin                               Merkel cell carcinoma                                                                                 63              15                                    23.8
  Skin            C44        Skin                               Cutaneous squamous cell carcinoma                                                                     123             101                                   82.1
  Lung            C39        Lung                               Spindle cell carcinoma of the lung                                                                    3               2                                     66.7
  Lung            C39        Lung                               Lymphoepithelioma-like carcinoma of the lung                                                          1               1                                     100.0
  Lung            C39        Lung                               Sarcomatoid carcinoma of the lung                                                                     15              7                                     46.7
  Breast          C50        Breast                             Adenoid cystic breast cancer                                                                          14              6                                     42.9
  Breast          C50        Breast                             Breast invasive mixed mucinous carcinoma                                                              43              4                                     9.3
  Urinary         C67        Bladder                            Plasmacytoid/signet ring cell bladder carcinoma                                                       6               5                                     83.3
  Urinary         C67        Bladder                            Sarcomatoid carcinoma of the urinary bladder                                                          2               1                                     50.0
  Urinary         C67        Bladder                            Small cell bladder cancer                                                                             2               1                                     50.0
  Urinary         C64        Kidney                             Renal non-clear cell carcinoma                                                                        146             8                                     5.5
  Others          C45, C48   Pleura, Peritonea                  Pleural mesothelioma                                                                                  75              1                                     1.3
  Others          C37        Thymus                             Thymic carcinoma                                                                                      10              4                                     40.0
  Others          C06        Head and neck                      Adenoid cystic carcinoma                                                                              323             147                                   45.5
  Others          C06        Head and neck                      Salivary adenocarcinoma                                                                               4               1                                     25.0
  Others          C06        Head and neck                      Salivary duct carcinoma                                                                               19              16                                    84.2
  Others          C06        Head and neck                      Epithelial-myoepithelial carcinoma                                                                    3               1                                     33.3
  Others          C80, C76   Unknown                            Cancer of unknown primary                                                                             149             60                                    40.3
  Summary                                                                                                                                                             4,901           1,006                                 20.5

*\#Each sample may have more than one targetable mutations, thus the prevalence may be over 100*.

Mutation Profiling of Chinese Patients With Rare Tumors
-------------------------------------------------------

We recruited a second, independent patient cohort from another pan-China database, Geneplus. One thousand three hundred and twelve patients (1312) with rare tumors were included for the study. The clinicopathological characteristics of all the patients are summarized in [Table 4](#T4){ref-type="table"}. The median age was 56, and 53.4% (700/1312) of the cohort were male. Ninety two percent (92.1%, 1209/1312) of the patients were at stage IV, and 58.6% (769/1312) of the patient were systemic treatment-naïve while 36% (472/1312) had been systemically treated. Tumor tissue was available for genetic analysis in 770 of these patients, while 469, 27, 16, 1, and 1 patient, respectively, had ctDNA, pleural effusion, peritoneal effusion, pericardial effusion, and cerebrospinal fluid (CSF) available as an alternative.

###### 

Clinicopathological characteristics of patients.

  **Characteristic**                                    **Pts. (*N* = 1,312)**
  ----------------------------------------------------- ------------------------
  **Clinicopathological characteristics of patients**   
  Age, years                                            
    median                                              56
    Range                                               2--97
  Gender                                                
    Female                                              612
    Male                                                700
  Clinical stage                                        
    I                                                   5
    II                                                  31
    III                                                 34
    IV                                                  1,209
    NA                                                  33
  Previous treatment                                    
    Surgery                                             71
    No systemic treatment                               769
    Systemically treated                                472
  Specimen                                              
    Tumor tissue                                        770
    ctDNA                                               496
    Pleural effusion                                    27
    Peritoneal effusion                                 16
    Pericardial effusion                                1
    CSF                                                 1

These 1,312 cases included 67 tumor subtypes out of our defined rare tumor types, with cancer of unknown primary, gastrointestinal stromal tumor, gallbladder cancer, intrahepatic cholangiocarcinoma, and sarcomatoid carcinoma of the lung as the top 5 tumors including 410, 107, 72, 70, and 51 patients, respectively.

Within these 1,312 samples, a total of 7,998 alterations were identified in 712 genes (5,924 base substitutions, 1,206 gene amplifications or deletions, 840 short indels, and 28 gene rearrangements) for a mean of 4 alterations per tumor ([Supplementary Table 6](#SM6){ref-type="supplementary-material"}). Total 701 targetable mutations were identified in the 1,312 samples, with *EGFR, KIT, CDKN2A, PIK3CA, PTEN, NF1, ERBB2, BRAF, BRCA2*, and *FGFR1/2/3* as the top 10 genes with targetable mutations identified in 266, 149, 119, 119, 112, 75, 66, 33, 33, 27, and 27 samples, respectively. Of the 1312 patients, 478 patients had at least 1 targetable mutation ([Table 5](#T5){ref-type="table"} and [Supplementary Table 7](#SM7){ref-type="supplementary-material"}).

###### 

Prevalence of targetable mutations in rare tumor samples from Chinese patients.

  **System**      **ICD**    **Site**                           **Tumors, including but not restricted to**                                                           **Number of cases**   **Cases with targetable gene alterations**   **Prevalence of targetable gene alterations \#(%)**   **Tissue**   **Number of patients with targetable gene alterations**
  --------------- ---------- ---------------------------------- ----------------------------------------------------------------------------------------------------- --------------------- -------------------------------------------- ----------------------------------------------------- ------------ ---------------------------------------------------------
  Digestive       C24        Biliary tract                      Perihilar cholangiocarcinoma                                                                          30                    12                                           40.0                                                  17           10
  Digestive       C24        Biliary tract                      Extrahepatic cholangiocarcinoma                                                                       4                     3                                            75.0                                                  4            3
  Digestive       C24        Biliary tract                      Intrahepatic cholangiocarcinoma                                                                       70                    24                                           34.3                                                  34           13
  Digestive       C23        Gallbladder                        Gallbladder cancer                                                                                    72                    26                                           36.1                                                  39           22
  Digestive       C17        Small bowel                        Small bowel well-differentiated neuroendocrine tumor                                                  2                     0                                            0.0                                                   2            0
  Digestive       C17        Small bowel                        Duodenal adenocarcinoma                                                                               38                    12                                           31.6                                                  22           8
  Digestive       C17        Small bowel                        Small intestinal carcinoma                                                                            32                    25                                           78.1                                                  18           14
  Endocrine       C74        Adrenal                            Adrenocortical carcinoma                                                                              10                    0                                            0.0                                                   7            0
  Endocrine       C75        Pituitary                          Pituitary carcinoma                                                                                   1                     1                                            100.0                                                 0            1
  Endocrine       C73        Thyroid                            Medullary thyroid cancer                                                                              15                    5                                            33.3                                                  13           5
  Neural system   C72, C70   Brain                              Anaplastic astrocytoma                                                                                6                     9                                            150.0                                                 6            6
  Neural system   C72, C70   Brain                              Anaplastic oligodendroglioma                                                                          2                     1                                            50.0                                                  2            1
  Neural system   C72, C70   Brain                              Anaplastic oligoastrocytoma                                                                           1                     0                                            0.0                                                   0            0
  Neural system   C72, C70   Brain                              Glioblastoma                                                                                          32                    74                                           231.3                                                 30           26
  Neural system   C72, C70   Brain                              Astrocytoma                                                                                           33                    13                                           39.4                                                  32           14
  Neural system   C72, C70   Brain                              Oligodendroglioma                                                                                     6                     0                                            0.0                                                   6            0
  Neural system   C72, C70   Brain                              Oligoastrocytoma                                                                                      2                     0                                            0.0                                                   0            0
  Neural system   C72, C70   Brain                              High-grade glioma(NOS)                                                                                5                     6                                            120.0                                                 5            4
  Neural system   C72, C70   Brain                              Primitive neuroectodermal tumor                                                                       7                     1                                            14.3                                                  4            1
  Neural system   C72, C70   Brain                              Medulloblastoma                                                                                       2                     0                                            0.0                                                   0            0
  Neural system   C72, C70   Brain                              Anaplastic meningioma                                                                                 1                     1                                            100.0                                                 0            1
  Neural system   C72, C70   Brain                              Meningioma                                                                                            10                    6                                            60.0                                                  5            6
  Neural system   C72, C70   Brain                              Rhabdoid meningioma                                                                                   1                     2                                            200.0                                                 1            1
  Neural system   C72, C70   Brain                              Malignant teratoma                                                                                    1                     0                                            0.0                                                   0            0
  Neural system   C72, C70   Brain                              Embryonal carcinoma                                                                                   2                     0                                            0.0                                                   1            0
  Neural system   C72, C70   Brain                              Choriocarcinoma                                                                                       1                     0                                            0.0                                                   1            0
  Neural system   C72, C70   Brain                              Ependymoma                                                                                            3                     1                                            33.3                                                  3            1
  Neural system   C72, C70   Brain                              Anaplastic ependymoma                                                                                 4                     2                                            50.0                                                  4            1
  Neural system   C47        Peripheral Nerve                   Malignant peripheral nerve sheath tumor                                                               5                     5                                            100.0                                                 4            2
  Reproductive    C60        Penile                             Penile squamous cell carcinoma                                                                        6                     7                                            116.7                                                 3            4
  Reproductive    C52, C51   Vulva/vagina                       Squamous cell carcinoma of the vulva/vagina                                                           8                     2                                            25.0                                                  3            2
  Reproductive    C52, C51   Vulva/vagina                       Vaginal adenocarcinoma                                                                                2                     0                                            0.0                                                   0            0
  Reproductive    C56        Ovary                              Dysgerminoma                                                                                          1                     0                                            0.0                                                   1            0
  Reproductive    C56        Ovary/vulva/vagina/brain/testis,   Embryonal carcinoma                                                                                   2                     0                                            0.0                                                   1            0
  Soft tissue     C49        Soft tissue                        Desmoplastic small-round-cell tumor                                                                   1                     0                                            0.0                                                   0            0
  Soft tissue     C49        Soft tissue                        Rhabdomyosarcoma                                                                                      16                    6                                            37.5                                                  9            6
  Soft tissue     C49        Soft tissue                        Synovial sarcoma                                                                                      16                    0                                            0.0                                                   15           0
  Soft tissue     C49        Soft tissue                        Myofibroma                                                                                            2                     0                                            0.0                                                   1            0
  Soft tissue     C49        Soft tissue                        Myxofibrosarcoma                                                                                      3                     3                                            100.0                                                 0            1
  Soft tissue     C49        Soft tissue                        Leiomyosarcoma                                                                                        48                    11                                           22.9                                                  34           9
  Soft tissue     C49        Soft tissue                        Alveolar soft part sarcoma                                                                            7                     0                                            0.0                                                   6            0
  Soft tissue     C49        Soft tissue                        Epithelioid sarcoma                                                                                   5                     0                                            0.0                                                   0            0
  Soft tissue     C49        Soft tissue                        Epithelioid hemangioendothelioma                                                                      2                     1                                            50.0                                                  1            1
  Soft tissue     C49        Soft tissue                        Dendritic cell sarcoma                                                                                1                     1                                            100.0                                                 0            1
  Soft tissue     C49        Soft tissue                        Clear cell sarcoma                                                                                    3                     1                                            33.3                                                  0            1
  Soft tissue     C49        Soft tissue                        Undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma/high-grade spindle cell sarcoma   12                    3                                            25.0                                                  7            2
  Soft tissue     C49        Soft tissue                        Gastrointestinal stromal tumor                                                                        107                   113                                          105.6                                                 82           79
  Soft tissue     C49        Soft tissue                        Fibrosarcoma                                                                                          7                     1                                            14.3                                                  6            1
  Soft tissue     C49        Soft tissue                        Angiosarcoma                                                                                          6                     1                                            16.7                                                  2            1
  Soft tissue     C49        Soft tissue                        Inflammatory myofibroblastic tumor                                                                    6                     0                                            0.0                                                   5            0
  Soft tissue     C49        Soft tissue                        Desmoid/aggressive fibromatosis                                                                       1                     0                                            0.0                                                   0            0
  Soft tissue     C49        Soft tissue                        Liposarcoma                                                                                           19                    1                                            5.3                                                   14           1
  Bone            C40, C41   Bone                               Chondrosarcoma                                                                                        6                     2                                            33.3                                                  6            1
  Bone            C40, C41   Bone                               Chordoma                                                                                              2                     0                                            0.0                                                   1            0
  Bone            C40, C41   Bone                               Osteosarcoma                                                                                          18                    2                                            11.1                                                  9            2
  Skin            C44        Skin                               Dermatofibrosarcoma protuberans                                                                       2                     1                                            50.0                                                  1            1
  Skin            C44        Skin                               Cutaneous squamous cell carcinoma                                                                     5                     3                                            60.0                                                  3            2
  Skin            C44        Skin                               Sebaceous carcinoma                                                                                   1                     0                                            0.0                                                   1            0
  Skin            C44        Skin                               Sweat gland adenocarcinoma                                                                            2                     3                                            150.0                                                 0            2
  Skin            C44        Skin                               Sweat gland carcinoma/apocrine eccrine carcinoma                                                      4                     3                                            75.0                                                  4            2
  Lung            C39        Lung                               Sarcomatoid carcinoma of the lung                                                                     51                    28                                           54.9                                                  28           20
  Urinary         C64        Kidney                             Renal non-clear cell carcinoma                                                                        49                    20                                           40.8                                                  21           14
  Others          C45, C48   Pleura, peritonea                  Pleural mesothelioma                                                                                  21                    3                                            14.3                                                  12           3
  Others          C45, C48   Pleura, peritonea                  Pleuropulmonary blastoma                                                                              2                     1                                            50.0                                                  0            1
  Others          C45, C48   Pleura, peritonea                  Peritoneal mesothelioma                                                                               12                    4                                            33.3                                                  6            3
  Others          C37        Thymus                             Thymic carcinoma                                                                                      48                    15                                           31.3                                                  25           12
  Others          C80, C76   Unknown                            Cancer of unknown primary                                                                             410                   236                                          57.6                                                  189          166
  Summary                                                                                                                                                             1,312                 701                                          53.4                                                  756          478

*\#Each sample may have more than one targetable gene alterations, thus the prevalence may over 100*.

Consistencies and Discrepancies Between the Two Cohorts of Rare Tumors
----------------------------------------------------------------------

Between the cBioPortal cohort and our independent cohort, there were 41 overlapping subtypes (41/63, cBioPortal; 41/67, our cohort) and 22 (cBioPortal) or 25 (our cohort) subtypes unique to each cohort ([Table 6](#T6){ref-type="table"}, [Supplementary Figure 1](#SM10){ref-type="supplementary-material"}).

###### 

Percentage of targetable mutation carrier in the two cohorts.

  **Gene**      **Genomic alteration**                **Approved targeted therapies**                                                     **cBioPortal (%)**   **Geneplus cohor (%)**
  ------------- ------------------------------------- ----------------------------------------------------------------------------------- -------------------- ------------------------
  *ALK*         Fusion                                **Crizotinib, Ceritinib, Alectinib**, Brigatinib                                    0.55                 1.07
  *ATM*         Substitution, truncation              **Olaparib**, Talazoparib, Rucaparib, Niraparib                                     1.53                 1.83
  *BRAF*        Substitution, fusion                  Vemurafenib, Dabrafenib, **Regorafenib, Sorafenib**, Trametinib                     0.67                 1.91
  *BRCA1*       Substitution, truncation              **Olaparib**, Talazoparib, Rucaparib, Niraparib                                     0.33                 0.23
  *BRCA2*       Substitution, truncation              **Olaparib**, Talazoparib, Rucaparib, Niraparib                                     0.55                 1.91
  *CDKN2A*      Loss, substitution, truncation        **Palbociclib**, Ribociclib, Abemaciclib                                            2.29                 7.24
  *EGFR*        Substitution                          **Erlotinib, Afatinib, Gefitinib, Icotinib, Osimertinib**, Lapatinib, Dacomitinib   0.47                 7.70
  *ERBB2*       Amplification, substitution           **Trastuzumab, Lapatinib, Pyrotinib**, Pertuzumab, **Trastuzumab-DM1, Afatinib**    0.53                 3.28
  *FGFR1,2,3*   Substitution, amplification, fusion   Erdafitinib, **Pazopanib**, Ponatinib                                               1.33                 1.91
  *KIT*         Substitution                          **Imatinib**                                                                        2.43                 7.32
  *MET*         Amplification                         **Crizotinib**, Cabozantinib                                                        0.18                 1.60
  *NF1*         Loss, truncation                      **Temsirolimus, Everolimus**, Trametinib                                            0.67                 4.34
  *NTRK1,2,3*   Fusion                                Larotrectinib                                                                       0.10                 0.08
  *PIK3CA*      Substitution, amplification           Alpelisib, **Temsirolimus, Everolimus**                                             5.39                 6.86
  *PTEN*        Loss, substitution, truncation        **Temsirolimus, Everolimus**                                                        2.98                 5.34
  *RET*         Fusion/substitution                   Cabozantinib, Ponatinib, Sorafenib, **Sunitinib**, Vandetanib, **Regorafenib**      0.37                 0.61
  *ROS1*        Fusion                                **Crizotinib, Ceritinib**                                                           0.04                 0.23

*Bold: approved by NMPA*.

We first compared the overall prevalence of TGAs in these two cohorts. The prevalence of targetable mutations was significantly higher in our cohort compared with the data from cBioPortal (53.4 vs. 20.4%, *p* \< 0.001) ([Table 6](#T6){ref-type="table"}). Specifically, mutations or amplifications of *BRAF, BRCA2, CDKN2A, EGFR, ERBB2, KIT, MET, NF1, ROS1* were 3 or more times more frequent in our cohort than in the cBioPortal cohort. Alterations of *BRCA1, NTRK* fusion were slightly more common in the cBioPortal cohort. When restricting analysis to the 41 overlapping subtypes, the difference of targetable mutations was still significant (54.1 vs. 26.1%, *p* \< 0.001). We further focused on 4 rare tumors (gallbladder cancer, astrocytoma, gastrointestinal stromal tumor, and cancer of unknown primary) with more than 30 cases in both cohorts. We found the overall incidence rate of targetable mutations was higher in our cohort ([Supplementary Table 8](#SM8){ref-type="supplementary-material"}). For gallbladder cancer, *ERBB2* and *BRCA2* mutations were significantly more frequent in our cohort, while *ATM* mutation was enriched in the cBioPortal cohort ([Figure 1A](#F1){ref-type="fig"}) ([@B23]). For astrocytoma, *BRAF, ATM, CDKN2A*, and *EGFR* mutations/amplifications were highly enriched in our cohort ([Figure 1B](#F1){ref-type="fig"}). For gastrointestinal stromal tumor, the prevalence of the *KIT* mutation was similar between the two groups, but our cohort had a significantly higher prevalence of *CDKN2A* and *NF1* ([Figure 1C](#F1){ref-type="fig"}). For cancer of unknown primary, *EGFR* mutation and *ALK* fusion were highly enriched in our cohort, which indicate that those tumors might originate from lung ([Figure 1D](#F1){ref-type="fig"}).

![Comparison of targetable mutations in gallbladder cancer **(A)**, astrocytoma **(B)**, gastrointestinal stromal tumor **(C)**, and cancer of unknown primary **(D)**.](fonc-10-00536-g0001){#F1}

Discussion {#s4}
==========

This study focused on rare tumors in China and proposed a novel definition of rare tumors customized for China by jointly considering frequency and clinical characteristics to addresses the disparate requirements of clinical decision-making, clinical research, drug development, and health care services. Applying this new definition, a comprehensive list of rare tumors was explored for genetic biomarkers of response to targeted therapy both in the worldwide cBioPortal database and a mainland China-specific patient cohort mainly to explore potential novel treatment indications for those rare tumors in China. Results show that targetable gene alterations are frequently present in rare tumors, and that these mutations are enriched in Chinese population as compared to the general global population.

Most importantly, a definition of rare tumors in China was proposed for the first time based on the epidemiology data and availability of standard treatment in China. An incidence of ≤2.5/100,000 per year as a cut off value for rare tumor in China is novel and it is rigorous compared with those of the USA and Europe which is 15/100,000 and 6/100,000 respectively. The disparity should be mainly attributed to the facts that China has a larger population base, and a different epidemiological distribution for most types of tumors compared to western countries. We believe any threshold for rarity is artificial and should be considered as just indicative. We should always be aware that an incidence threshold rate as a line for rareness should be used with flexibility. The most important purpose of proposing the definition is to increase the attention from clinical practitioners and government personnel of China, as well as drug investigators all over the world, to promote the development of novel drugs and strategies for those rare tumors without consensus and guidelines for effective treatment in China, and finally to improve the outcome of rare tumor patients.

After applying our rare tumor criteria to patient data, we discovered the overall prevalence of TGAs in Chinese rare tumor patients\' cohort was much higher than that of the cBioPortal cohort. We restricted our analysis of TGAs to genes having Level 1-4 evidence of being a cancer gene according to the OncoKB knowledge database. Using this framework, we identified mutations of *ALK, ATM, BRAF, BRCA1, BRCA2, CDKN2A, EGFR, ERBB2, FGFR1,2,3, KIT, MET, NF1, NTRK1,2,3, PIK3CA, PTEN, RET*, and *ROS1* within our cohort. The cumulative prevalence of TGAs was significantly higher in Chinese cohort (53.43%) compared with general population worldwide (26.1%). This indicates that there might be higher possibilities those patients could benefit from targeted therapies. The underlying causes for the disparities in mutation prevalence were complicated as the two cohorts had significantly different compositions of tumor subtypes, as well as different numbers of patients in each subtype. The overall difference between the two cohorts was still significant (*p* \< 0.001) if we only studied the shared 41 subtypes of rare tumor. This phenomenon is in agreement with the data showing that *EGFR* mutation rate in Asian NSCLC patients is higher than that of Caucasian patients. Our findings indicate that the classification of "rare tumor" is heterogeneous by ethnicity.

We also found that most common TGAs in both cohorts are actionable with available drugs. The top 5 targetable mutations found in Chinese patients cohort were *EGFR, KIT, CDKN2A, PIK3CA*, and *PTEN*; and in the cBioPortal cohort were *PIK3CA, PTEN, KIT, CDKN2A*, and *ATM*. Regarding the 4 shared targetable mutations, there is at least one targeted drug for each mutation (imatinib for *KIT*, palbociclib for *CDKN2A*, temsirolimus and everolimus for *PIK3CA* and *PTEN*) currently available in China ([Table 6](#T6){ref-type="table"}). This suggests that we have available effective treatment options for some rare tumor patients.

Finally, our data indicate that samples for genetic profiling of rare tumor are still inadequate. There are only 10.5% (4901/46566) tumor samples from rare tumors in cBioPortal database. Moreover, 52 out of 141 (36.9%) subtypes of rare tumors did not have genetic data available in cBioPortal or in our cohort ([Supplementary Table 9](#SM9){ref-type="supplementary-material"}). For most subtypes with data, the median number of samples was 19 in cBioPortal and 5 in our cohort. Considering the high prevalence of TGAs in the rare tumor population and the largely unmet medical needs of those patients, more attention and efforts should be applied in this field in the near future.

Conclusions {#s5}
===========

We defined rare tumor in China as ICD-specified tumors with incidence ≤2.5/100,000 per year in China, and subtypes of non-rare ICD-specified tumors with incidence ≤2.5/100,000 per year in China, and cancers of unknown primary. Genomic profiling of rare tumors matching this definition from cBioPortal and a Chinese cohort drawn from the Geneplus database demonstrated a substantial prevalence of targetable genomic alterations in these tumors, which was even higher in Chinese rare tumor patient population than in the general population. All of the above facilitates future drug investigations and treatment improvement for rare tumors.
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NGS

:   Next generation sequencing

TGAs

:   targetable genomic alterations

cBioPortal

:   CBio Cancer Genomics Portal

ESMO

:   European Society for Medical Oncology

NCI

:   National Cancer Institute

FDA

:   Food and Drug Administration

ICD

:   International Classification of Diseases

CNKI

:   China National Knowledge Infrastructure

CUP

:   cancers of unknown primary

MSK

:   Memorial Sloan Kettering Cancer Center

SNV

:   Single nucleotide variants

InDels

:   insertions and deletions

CSF

:   cerebrospinal fluid.
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